204 related articles for article (PubMed ID: 2537051)
1. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist.
Nichols WW; Mehta J; Wargovich TJ; Franzini D; Lawson D
Angiology; 1989 Mar; 40(3):209-21. PubMed ID: 2537051
[TBL] [Abstract][Full Text] [Related]
2. Reduction in myocardial neutrophil accumulation and infarct size following administration of thromboxane inhibitor U-63,557A.
Wargovich TJ; Mehta J; Nichols WW; Ward MB; Lawson D; Franzini D; Conti CR
Am Heart J; 1987 Nov; 114(5):1078-85. PubMed ID: 2960223
[TBL] [Abstract][Full Text] [Related]
3. Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
Hock CE; Phillips GR; Lefer AM
Prostaglandins Leukot Med; 1985 Mar; 17(3):339-46. PubMed ID: 3857643
[TBL] [Abstract][Full Text] [Related]
4. TxA2 inhibition and ischemia-induced loss of myocardial function and reactive hyperemia.
Mehta JL; Nichols WW; Schofield R; Donnelly WH; Chandna VK
Am J Physiol; 1990 May; 258(5 Pt 2):H1402-8. PubMed ID: 2159727
[TBL] [Abstract][Full Text] [Related]
5. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro.
O'Keefe EH; Liu EC; Greenberg R; Ogletree ML
Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501
[TBL] [Abstract][Full Text] [Related]
6. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
7. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
8. Effect of cyclooxygenase and thromboxane synthetase inhibition on furosemide-stimulated plasma renin activity.
Datar S; McCauley FA; Wilson TW
Can J Physiol Pharmacol; 1987 Jan; 65(1):80-3. PubMed ID: 3105853
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
Ito T; Toki Y; Hieda N; Okumura K; Hashimoto H; Ogawa K; Satake T
Jpn Circ J; 1989 Sep; 53(9):1115-21. PubMed ID: 2513429
[TBL] [Abstract][Full Text] [Related]
10. Modulation of human neutrophil superoxide production by selective thromboxane synthetase inhibitor U63,557A.
Mehta JL; Lawson D; Mehta P
Life Sci; 1988; 43(11):923-8. PubMed ID: 2842563
[TBL] [Abstract][Full Text] [Related]
11. Testing the "redirection hypothesis" of prostaglandin metabolism in the kidney.
Datar S; McCauley FA; Wilson TW
Prostaglandins; 1987 Feb; 33(2):275-85. PubMed ID: 3296006
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of a thromboxane synthetase inhibitor in traumatic shock.
Hock CE; Lefer AM
Circ Shock; 1984; 14(3):159-68. PubMed ID: 6542462
[TBL] [Abstract][Full Text] [Related]
13. G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in rats.
Squadrito F; Ioculano M; Altavilla D; Zingarelli B; Canale P; Campo GM; Saitta A; Oriti S; Spignoli G; Caputi AP
Pharmacology; 1993 Sep; 47(3):167-75. PubMed ID: 8415867
[TBL] [Abstract][Full Text] [Related]
14. Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury.
Squadrito F; Ioculano M; Altavilla D; Zingarelli B; Canale P; Campo GM; Saitta A; Oriti S; Faggiotto A; Caputi AP
Agents Actions; 1993 Jul; 39(3-4):143-9. PubMed ID: 8304242
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Fitzgerald DJ; Fragetta J; FitzGerald GA
J Clin Invest; 1988 Nov; 82(5):1708-13. PubMed ID: 3183064
[TBL] [Abstract][Full Text] [Related]
16. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia.
Hock CE; Brezinski ME; Lefer AM
Eur J Pharmacol; 1986 Mar; 122(2):213-9. PubMed ID: 3011442
[TBL] [Abstract][Full Text] [Related]
17. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
Grover GJ; Schumacher WA; Simon M; Parham C
J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia.
Brezinski ME; Yanagisawa A; Lefer AM
J Cardiovasc Pharmacol; 1987 Jan; 9(1):65-71. PubMed ID: 2434797
[TBL] [Abstract][Full Text] [Related]
19. CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
Hock CE; Lefer AM
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):285-94. PubMed ID: 3755540
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of U-63,557A, a thromboxane synthetase inhibitor, in an ovine model of pregnancy-induced hypertension.
Keith JC; Thatcher CD; Schaub RG
Am J Obstet Gynecol; 1987 Jul; 157(1):199-203. PubMed ID: 3605254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
